Immutep Limited (IMM) Fair Value & Analysis
Healthcare · AU · Market cap A$70.7M
Fair value as of: Jun 26, 2026
From 1 valuation models · updated 4 days ago
Fair value updated Jun 26, 2026 — revised from A$0.4400 to A$0.0709 (−83.9%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range A$0.0346 – A$0.4426 · fair‑value band A$0.0556 – A$0.0862 · the A$0.0510 price screens below the A$0.0709 fair value. As of Jun 26, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
Immutep Limited (IMM) currently trades at A$0.0510, while our model-based Fair Value estimate is A$0.0709 — implying the stock looks roughly 39.0% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Trailing-twelve-month revenue stands at A$7.9M. Revenue grew 91.5% year over year. It earns a return on equity of -61.9%. The balance sheet holds a net cash position of A$65.8M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Immutep Limited reported revenue of A$5.0M in FY2025 versus A$3.9M in FY2021, a compound +6.9%/yr. Reported net income was −A$61.4M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$574.00 | R$357.63 | -38% |
| Regeneron Pharmaceuticals, Inc REGN | $601.65 | $577.20 | -4% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $288.18 | $51.70 | -82% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Immutep Limited (IMM) undervalued?
What is the fair value of IMM?
What is the quality score of IMM?
What is the revenue of Immutep Limited (IMM)?
What is the net profit margin of IMM?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.